SCHEMBL3489281

SCHEMBL3489281

CCNS(=O)(=O)c1c(N)cc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 8/20 0.46
NR3C2 P08235 7/20 0.46
CYP3A4 P08684 3/20 0.46
PGR P06401 4/20 0.44
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
VCAM1 P19320 1/20 0.40
TP53 P04637 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
CCR10 P46092 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
ACLY P53396 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490788 0.87 CA1 (0.45) NR3C1NR3C2CYP3A4PGRALDH1A1
SCHEMBL3490280 0.84 NR3C1 (0.42) NR3C1NR3C2CYP3A4PGRALDH1A1
SCHEMBL3489059 0.82 CYP3A4 (0.47) NR3C1NR3C2CYP3A4PGRTP53
SCHEMBL3490267 0.82 CYP3A4 (0.47) NR3C1NR3C2CYP3A4PGRTP53
SCHEMBL3489898 0.81 NR3C1 (0.44) NR3C1NR3C2CYP3A4PGRGAA
SCHEMBL9275311 0.81 TP53 (0.41) NR3C1NR3C2CYP3A4PGRALDH1A1
SCHEMBL9220640 0.79 NR3C1 (0.42) NR3C1NR3C2CYP3A4PGRALDH1A1
SCHEMBL9220154 0.79 ALDH1A1 (0.44) NR3C1NR3C2CYP3A4PGRALDH1A1
SCHEMBL3489075 0.78 ALDH1A1 (0.52) NR3C1NR3C2PGRALDH1A1KDM4E
SCHEMBL3488631 0.78 KMT2A (0.52) NR3C1NR3C2CYP3A4PGRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-02-11 US disclosed
EP-2007760-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-12-31 EP disclosed
WO-2007108569-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035866-A1 NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME OPRD1, HTR6, HTR1D NR3C1 247/4885NR3C2 335/4885CYP3A4 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.